Entero Therapeutics Inc. (ENTO)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
0.59
0.00 (0.20%)
At close: Jan 14, 2025, 3:58 PM
0.56
-5.85%
After-hours Jan 14, 2025, 03:59 PM EST
undefined% (undefined)
Bid | 0.45 |
Market Cap | 2.80M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 14.17 |
PE Ratio (ttm) | 0.04 |
Forward PE | n/a |
Analyst | n/a |
Ask | 0.7 |
Volume | 21,238 |
Avg. Volume (20D) | 260,278 |
Open | 0.54 |
Previous Close | 0.59 |
Day's Range | 0.54 - 0.59 |
52-Week Range | 0.18 - 9.35 |
Beta | undefined |
About ENTO
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2016
Employees 9
Stock Exchange NASDAQ
Ticker Symbol ENTO
Website https://www.firstwavebio.com
2 months ago ·
Source
+1.61%
Entero Therapeutics shares are trading lower. The ...
Unlock content with
Pro Subscription